CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 100 enrolled
Drug / intervention
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water +3 moredrug
Likely dose
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of waterfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02400333
NCT02400333Phase 1Completed
CompareCT.gov

An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects

AstraZeneca·interventional·Posted Mar 27, 2015·Updated Sep 29, 2016

In Brief

A Phase 1 clinical trial evaluating Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, and 2 other interventions for Bioavailability and Healthy Subjects. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This study will be an open-label, randomised, four-period, four-treatment, crossover study in healthy male and female of non-childbearing potential subjects, performed at a single study centre. The objective of the study is to assess the bioavailability of ticagrelor orodispersible (OD) tablets when administered with water, without water and suspended in water to be administered through nasogastric tubes, compared to ticagrelor immediate-release (IR) tablets

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBioavailability, Healthy Subjects
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 27, 2015
Enrollment StartJun 1, 2015
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.3 years ago

Interventions

Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of waterdrug

90 mg single dose

Ticagrelor OD tablet (90 mg single dose) administered without waterdrug

90 mg single dose

Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tubedrug

90 mg single dose

Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterdrug

90 mg single dose